-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AbbVie recently announced the evaluation of an oral JAK1 inhibitor Rinvoq (upadacitinib, upatinib, 15 mg, once daily) for the treatment of patients with rheumatoid arthritis (RA) in the Phase 3 SELECT-BEYOND clinical trial of a post-mortem analysis New data
The SELECT-BEYOND trial enrolls patients with moderate to severe RA who are receiving stable traditional synthetic disease-modifying anti-rheumatic drugs (csDMARD) and have previously had insufficient or intolerant responses to at least one biological DMARD (bDMARD) Subject to
The results showed that 34% of patients treated with Rinvoq+ background csDMARD achieved clinical disease activity index remission (CDAI ≤ 2.
Of the patients who received Rinvoq treatment and lost CDAI remission, 58% still maintained CDAI LDA, and 22% returned to remission before the analysis deadline
SELECT-BEYOND clinical trial post-mortem analysis data
The active pharmaceutical ingredient of Rinvoq is upadacitinib, which is an oral selective and reversible JAK1 inhibitor discovered and developed by AbbVie.
Up to now, in the European Union, Rinvoq 15mg has been approved for 4 indications: (1) for the treatment of moderate to severe rheumatoid arthritis (RA) adult patients; (2) for the treatment of active psoriatic arthritis (PsA) for adult patients; (3) for the treatment of adult patients with active ankylosing spondylitis (AS); (4) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) and adolescent patients 12 years and older
In the United States, Rinvoq 15mg is only approved for 1 indication: it is used to treat adults with moderate to severe rheumatoid arthritis (RA)
Currently, Rinvoq treats ulcerative colitis (UC), rheumatoid arthritis (RA), psoriatic arthritis (PsA), atopic dermatitis (AD), axial spondyloarthritis (axSpA), Crohn The Phase 3 clinical studies of En's disease (CD) and giant cell arteritis (GCA) are underway
Note: The original text has been deleted
Original source: AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
